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Abstract 
Intracellular glucocorticoid reactivation is catalyzed by 11β-hydroxysteroid dehydrogenase 1 
(11β-HSD1), which functions predominantly as a reductase in cells expressing hexose-6-
phosphate dehydrogenase (H6PDH). We recently showed that the ratios of cortisone to cortisol 
and 7-keto- to 7-hydroxy-neurosteroids are regulated by 11β-HSD1 and very much depend on 
co-expression with H6PDH, providing cosubstrate NADPH. Here, we investigated the impact of 
H6PDH on the modulation of 11β-HSD1-dependent inter-conversion of cortisone and cortisol by 
inhibitors and alternative substrates. Using HEK-293 cells expressing 11β-HSD1 or co-
expressing 11β-HSD1 and H6PDH, we observed significant differences of 11β-HSD1 inhibition 
by natural and pharmaceutical compounds as well as endogenous hormone metabolites. 
Furthermore, we show potent and dose-dependent inhibition of 11β-HSD1 by 7-keto-DHEA in 
differentiated human THP-1 macrophages and in HEK-293 cells over-expressing 11β-HSD1 
with or without H6PDH. In contrast, 7-ketocholesterol (7-KC) did not inhibit 11β-HSD1 in 
HEK-293 cells, even in the presence of H6PDH, but inhibited 11β-HSD1 reductase activity in 
differentiated THP-1 macrophages (IC50 = 8.1 ± 0.9 μM). 7-keto-DHEA but not 7-KC inhibited 
11β-HSD1 in HEK-293 cell lysates. In conclusion, cellular factors such as H6PDH can 
significantly modulate the effect of inhibitors and alternative 7-oxygenated substrates on 
intracellular glucocorticoid availability. 
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Introduction 
Glucocorticoid excess and locally disturbed glucocorticoid metabolism contribute to 
metabolic diseases (Atanasov and Odermatt, 2007). Understanding of the underlying 
mechanisms is indispensable for efficient treatment and prevention of these pathologies. In cells, 
glucocorticoids are activated by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which 
converts cortisone to cortisol (or 11-dehydrocorticosterone to corticosterone in rodents). The 
major expression sites of 11β-HSD1 are liver, skeletal muscles and white adipose tissue, but it is 
also present in other organs such as brain and macrophages. In the latter, 11β-HSD1 can 
contribute to the immune response and increase the phagocytic capacity of macrophages 
(Gilmour et al., 2006). 
Inside the cell, the enzyme is anchored in the endoplasmic reticulum (ER) membrane 
(Frick et al., 2004, Odermatt et al., 1999), with the catalytic site facing the lumen. The ER lumen 
is characterized by an oxidative environment with an estimated ratio of oxidized to reduced 
glutathione of 1:1-3 (Braakman et al., 1992). To act as a reductase, 11β-HSD1 (and probably 
other reductive enzymes inside the ER (Hori and Takahashi, 1974)) is dependent on the supply 
of NADPH. This can be achieved by hexose-6-phosphate dehydrogenase (H6PDH), which 
converts glucose-6-phosphate to 6-phosphogluconolactone and represents the ER-luminal 
analogue of the cytoplasmic glucose-6-phosphate dehydrogenase (Atanasov et al., 2004, 
Banhegyi et al., 2004, Bujalska et al., 2005). Moreover, direct interaction between 11β-HSD1 
and H6PDH seems to be important for efficient reduction of cortisone (Atanasov et al., 2008). 
Importantly, mice lacking H6PDH are unable to convert 11-dehydrocorticosterone to 
corticosterone (Lavery et al., 2006). 
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Besides glucocorticoids, 11β-HSD1 binds some 7-oxygenated steroids and sterols in a 
rotated orientation and catalyzes their metabolism at position 7 (Nashev et al., 2007, Odermatt et 
al., 2006). Alternative 11β-HSD1 substrates include 7-ketocholesterol (7-KC) (Hult et al., 2004, 
Schweizer et al., 2004, Song et al., 1998), one of the major constituents of the atherosclerotic 
plaque, as well as 7-oxygenated dehydroepiandrosterone (DHEA) and pregnenolone metabolites 
(Muller et al., 2006, Nashev et al., 2007, Robinzon et al., 2003), which are important 
neurosteroids. Recently, we demonstrated that the direction of 11β-HSD1-catalyzed conversion 
of these substances very much depends on the presence of H6PDH in cellular systems (Nashev et 
al., 2007). 
Here, we investigate the impact of H6PDH on the inhibitory potency of natural and 
pharmaceutical compounds as well as alternative substrates for 11β-HSD1, which may be 
relevant for efficacy and safety assessment of 11β-HSD1 inhibitors. Importantly, in some cells, 
e.g. in certain regions of the brain, 11β-HSD1 seems not to colocalize with H6PDH, as indicated 
by a recent expression study in the rat (Gomez-Sanchez et al., 2008). In addition, both 11β-
HSD1 reductase and dehydrogenase activities have been measured in Leydig cells (Latif et al., 
2005, Tomlinson et al., 2004), despite colocalization with H6PDH in these cells (Gomez-
Sanchez et al., 2008). We used HEK-293 cells expressing 11β-HSD1 with or without H6PDH 
and measured the effect of inhibitors on the reduction of cortisone to cortisol in intact cells. In 
addition, we determined the impact of 7-keto and 7-hydroxy metabolites of cholesterol and 
DHEA on 11β-HSD1-dependent cortisone reduction in a relevant endogenous model, i.e. 
differentiated THP-1 macrophages. Our results show that H6PDH (and thus luminal NADPH 
availability) can influence the inhibitory potential of various compounds. Furthermore, we show 
that the alternative substrate 7-KC can inhibit 11β-HSD1 in differentiated THP1 macrophages. 
To begin to understand catalysis of 7-KC by 11β-HSD1, we constructed 3D models of 
11β-HSD1 and NADP(H) complexed with either 7-KC or 7β-hydroxycholesterol (7β-OHC), a 
method that we previously used to investigate how 11β-HSD1 catalyzes the formation of 7α-
hydroxy- and 7β-hydroxy-DHEA from 7-keto-DHEA (Nashev et al., 2007). In that study, we 
found that 11β-HSD1 catalysis of 7-keto-DHEA to either 7α-hydroxy- or 7β-hydroxy-DHEA 
depended on whether the A ring or D ring of DHEA was oriented towards the interior of 11β-
HSD1. Here, we report that analysis of the catalytic site of 3D models of 11β-HSD1 complexed 
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with NADP(H) and either 7-KC or 7β-OHC locates both steroids with their A ring oriented 
towards the interior of 11β-HSD1, which is the opposite orientation of glucocorticoids (Odermatt 
et al., 2006, Zhang et al., 2005). In our 3D model we find a favorable configuration of the 
catalytically important Tyr183 with 7-carbonyl on 7-KC but the distances between 7β-hydroxyl 
on 7β-OHC and the C4 atom on the nicotinamide ring of NADP+ increases, which may explain 
the less efficient interconversion of 7-oxycholesterols compared with glucocorticoids by 11β-
HSD1. 
 
Materials and Methods 
Materials. Cell culture media were purchased from Invitrogen (Carlsbad, CA) and Sigma 
(Buchs, Switzerland), [1,2,6,7-3H]-cortisone from American Radiolabeled Chemicals (St. Louis, 
MO), [1,2,6,7-3H]-cortisol from Amersham Pharmacia (Piscataway, NJ, USA), 5H-1,2,4-
triazolo(4,3-a)azepine,6,7,8,9-tetrahydro-3-tricyclo(3·3·1·13·7)dec-1-yl (T0504) from Enamine 
(Kiev, Ukraine) and steroids and oxysterols from Steraloids (Wilton, NH). BNW7 and BNW16 
were kindly provided by Dr. Thomas Wilckens, BioNetWorks GmbH (Munich, Germany). All 
other chemicals were from Fluka AG (Buchs, Switzerland) of the highest grade available. 
Cell culture.  HEK-293 cells stably transfected with human recombinant 11β-HSD1 
(subsequently referred to as AT6) (Schweizer et al., 2003) or with both human 11β-HSD1 and 
human H6PDH (subsequently referred to as HHH7) (Gumy et al., manuscript submitted 
elsewhere) were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 
10% fetal calf serum (FCS), 50 units/ml penicillin, 50 µg/ml streptomycin and 2 mM glutamine. 
THP-1 monocytes were generously provided by Dr. Brigitte Frey (University of Berne, 
Switzerland), and cultured in RPMI-1640 medium, supplemented with 10% FCS, 50 units/ml 
penicillin, 50 µg/ml streptomycin and 2 mM glutamine. Seventy-two hours prior to the 
experiment, cells were differentiated to macrophages by adding phorbol 12-myristate 13-acetate 
to the medium at a final concentration of 20 nM.  
Determination of 11β-HSD1 activity.  Enzymatic activities were determined in cell lysates and 
in intact cells as described previously (Nashev et al., 2007, Schuster et al., 2006). The reductase 
reaction was measured in a final volume of 20 μl containing 10 nCi [1,2,6,7-3H]-cortisone, 200 
nM unlabeled cortisone, 400 μM NADPH and various concentrations of inhibitors or steroid and 
sterol metabolites. Dehydrogenase activity was measured in the presence of 10 nCi radiolabeled 
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cortisol, 50 nM unlabeled cortisol and 400 μM NADP+. For measurements in intact cells, 50’000 
cells were seeded per well of poly-L-lysine coated 96-well Biocoat plates (Becton-Dickinson, 
Basel, Switzerland). The medium was replaced 24 h later by 80 μl fresh medium containing 
appropriate concentrations of inhibitors or steroid and sterol metabolites and 10 μl medium 
containing 10 nCi [1,2,6,7-3H]-cortisone and 200 nM unlabeled cortisone. Cells were incubated 
for 30 min (HHH7) or 2 h (AT6) at 37°C, reactions stopped by adding an excess of unlabeled 
cortisone and cortisol in methanol, followed by separation of steroids by thin layer 
chromatography (TLC) and determination of the conversion of radiolabeled substrate by 
scintillation counting.  
Differentiated THP-1 macrophages were incubated for 6 h with appropriate 
concentrations of 7-oxygenated sterols and steroids and activity assays were performed as 
described above. The remaining intact monolayers were washed twice with ice-cold PBS and 
lysed in 0.2 N NaOH containing 0.1% SDS (2 h, 4°C), and aliquots of the lysates were used to 
determine cellular protein content using the Pierce-BCA assay kit (Thermo Scientific, Rockford, 
IL, USA). Data (mean ± S.D.) were obtained from at least four independent experiments. 
3D-Models of 11β-HSD1.  Mouse 11β-HSD1 (PDB ID:1Y5R) was extracted from the Protein 
Data Bank (PDB) for use as a template to investigate the interactions of 7-KC and 7β-OHC with 
11β-HSD1. We used 1Y5R because it contains both corticosterone and NADP+, which allows us 
to superimpose C7-cholesterol analogs on corticosterone (Zhang et al., 2005). Cholesterol was 
extracted from PDB file 1N83. We converted cholesterol to 7-KC and 7β-OHC using the 
Biopolymer option in Insight II. Then we minimized the energy of each model of 11β-HSD1 
with C7-cholesterol analogs using Discover 3, which was run for 10,000 iterations, using a 
distant dependent dielectric constant of 2. 
Results and Discussion 
 Knowledge on the molecular mechanisms of the intracrine regulation of glucocorticoid 
homeostasis is essential to understand the mechanisms of various complex diseases, including 
the metabolic syndrome. The association of elevated glucocorticoid activation by 11β-HSD1 
with metabolic diseases has stimulated efforts to identify selective inhibitors for this enzyme and 
to explore the consequences of systemic inhibition. Regulation of glucocorticoid action is highly 
dynamic and tissue-specific. The recent identification of H6PDH as a determinant for the 
function of 11β-HSD1 as a reductase (Atanasov et al., 2004, Banhegyi et al., 2004, Bujalska et 
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al., 2005) and evidence from expression analyses of the two enzymes (Gomez-Sanchez et al., 
2008) indicate significant tissue-specific regulation of glucocorticoid reactivation by 11β-HSD1. 
Moreover, 11β-HSD1 plays a role in the metabolism of 7-KC (Hult et al., 2004, Schweizer et al., 
2004, Song et al., 1998) and 7-oxygenated neurosteroids (Muller et al., 2006, Nashev et al., 
2007, Robinzon et al., 2003). These so-called alternative functions suggest a role for 11β-HSD1 
in detoxification reactions which might be beneficial, further highlighting the importance of 
studying the tissue-specific functions of 11β-HSD1 and the relevance of H6PDH. Therefore, we 
investigated the influence of H6PDH on the effects of inhibitors and alternative substrates on 
11β-HSD1-dependent conversion of cortisone to cortisol.  
Impact of H6PDH on effects of 11β-HSD1 inhibitors in intact cells 
Because the substrate to cosubstrate ratio seems to have a major impact on 11β-HSD1 
activity (and thus on its inhibition) (Castro et al., 2007, Dzyakanchuk et al., 2008), we 
hypothesized that the presence or absence of H6PDH influences the potency of 11β-HSD1 
inhibitors, particularly of own endogenous substrates (Table 1). 
Table 1.  Inhibition of human 11β-HSD1 dehydrogenase and reductase activities in cell 
lysates. 11β-HSD activities were determined in lysates of HEK-293 cells expressing the 
corresponding human recombinant enzyme as described in “Materials and Methods”. Data 
represent IC50 values in μM (mean ± S.D.) from four independent experiments. n. d. = not 
detectable. 
Compound 11β-HSD1 
oxidation 
11β-HSD1 
reduction 
Glycyrrhetinic acid 0.23 ± 0.02 0.40 ± 0.08a 
Abietic acid 1.90 ± 0.38 5.4 ± 0.4a 
Flavanone n. d. 21 ± 3a 
2'-Hydroxyflavanone 37 ± 5 24 ± 3a 
T0504 0.041 ± 0.011 0.021 ± 0.003a 
BNW7 n. d. 2.0 ± 0.2 b 
BNW16 0.39 ± 0.08 0.144 ± 0.027 b 
7-ketodehydroepiandrosterone 29 ± 5c 0.82 ± 0.07 c 
7α-hydroxydehydroepiandrosterone 16 ± 1c 45 ± 2c 
7β-hydroxydehydroepiandrosterone 0.54 ± 0.05 c 7.7 ± 0.8 c 
7-ketopregnenolone 5.4 ± 0.5 c 0.68 ± 0.11 c 
7β-hydroxypregnenolone 1.34 ± 0.49 c 2.4 ± 0.5 c 
5α-androstan-3β-ol-7,17dione 18 ± 1 c 0.50 ± 0.11 c 
Values are from a(Arampatzis et al., 2005); b(Schuster et al., 2006) and c(Nashev et al., 2007) 
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Therefore, we measured 11β-HSD1 activity in HEK-293 cells stably expressing 11β-HSD1 
alone or together with H6PDH. As shown in Table 2, we found that in the presence of H6PDH, 
the required inhibitory concentration of many compounds underwent significant changes. 
 
Table 2.  Inhibition of human 11β-HSD1 in the absence or presence of H6PDH measured in 
intact cells. The reduction of cortisone by 11β-HSD1 was determined in intact HEK-293 cells 
expressing recombinant enzyme as described in “Materials and Methods”. Data represent IC50 
values in μM and are mean ± S.D. from four independent experiments.  
 
Compound 11β-HSD1 
 
11β-HSD1 
H6PDH 
Glycyrrhetinic acid 0.95 ± 0.32 0.55 ± 0.14 
Abietic acid 14.4 ± 2.3 7.5 ± 0.74 
Flavanone 0.51 ± 0.15 4.0 ± 1.2 
2'-Hydroxyflavanone 2.5 ± 0.6 2.7 ± 0.7 
T0504 0.139 ± 0.023 0.015 ± 0.001 
BNW7 0.54 ± 0.05 5.2 ± 0.7 
BNW16 2.3 ± 0.2 0.41 ± 0.08 
7-ketodehydroepiandrosterone 0.37 ± 0.12 0.42 ± 0.05 
7α-hydroxydehydroepiandrosterone stimulation 105 ± 10 
7β-hydroxydehydroepiandrosterone stimulation 25 ± 4 
7-ketopregnenolone 0.38 ± 0.09 0.151 ± 0.016 
7β-hydroxypregnenolone stimulation 6.4 ± 0.1 
5α-androstan-3β-ol-7,17dione 0.144 ± 0.017 0.45 ± 0.02 
 
 
For flavanone, a potent inhibitor of 11β-HSD1 reductase activity in intact cells not expressing 
H6PDH, eight times higher concentrations were required to obtain comparable inhibition rates in 
the presence of H6PDH. In cell lysates, flavanone did not inhibit the dehydrogenase reaction and 
was a relatively weak inhibitor of the reductase activity (Table 1). In contrast, the IC50 values of 
2’-hydroxyflavanone were similar in 11β-HSD1 versus 11β-HSD1 and H6PDH expressing intact 
cells, and 2’-hydroxyflavanone inhibited both dehydrogenase and reductase activities of 11β-
HSD1 in cell lysates, although at relatively high concentrations (Table 1). The synthetic 
compound T0504 (also known as Merck-544) displayed a ten-fold higher potency in the 
presence of H6PDH than in its absence (Table 2). The pharmaceutical compounds BNW7 and 
BNW16 also showed differences in their inhibitory potential upon coexpression with H6PDH. 
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The IC50 for 11β-HSD1 of BNW7 was 10-fold higher and that of BNW16 approximately 6-fold 
lower upon coexpression with H6PDH. 
The 7-keto steroids 7-keto-DHEA, 7-ketopregnenolone and 5α-androstane-3β-ol-7,17-
dione, which are substrates for the 11β-HSD1 reductase activity (Nashev et al., 2007), showed 
comparable IC50 values in cells expressing 11β-HSD1 alone or together with H6PDH. In lysates, 
they showed a strong preference to inhibit the reductase activity of 11β-HSD1. In contrast, the 
corresponding 7-hydroxy metabolites preferentially inhibited the dehydrogenase activity of 11β-
HSD1 in lysates, whereas they were weak inhibitors of the reductase activity in intact cells 
expressing H6PDH, and even showed a concentration-dependent stimulation of the reductase 
activity at lower concentrations in the absence of H6PDH (Fig. 1).  
This observation remains an enigma. A possible explanation is that inhibition of the 
dehydrogenase activity of the reversible 11β-HSD1 enzyme by the 7β-hydroxy metabolites 
results in a higher net conversion of cortisone to cortisol. In the presence of H6PDH, the 
reductase reaction is predominant in vivo and inhibition of the dehydrogenase reaction by 7β-
hydroxysteroids has a negligible effect. However, the same explanation is not valid for the 
reverse reaction, because no stimulation of the dehydrogenase activity could be observed in the 
presence of 7-ketosteroids (data not shown), suggesting differences in the sequential binding 
mechanism between the reductase and dehydrogenase reaction. Castro et al. suggested that the 
inhibitory potency of carbenoxolone is strongly influenced by the presence of NADPH and 
substrate in the assay buffer. The apparent Ki values for carbenoxolone decreased at high 
concentrations of NADPH, suggesting that carbenoxolone behaved as competitive inhibitor 
against cortisone and as noncompetitive inhibitor against NADPH (Castro et al., 2007). 
Nevertheless, the kinetic parameters of each inhibitor need to be examined individually, because 
the presence of sufficient amount of NADPH, the substrate: cofactor: inhibitor ratio and the 
mode of inhibition may provide an explanation for the observed differences. 
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Figure 1.  Effect of 7-oxygenated DHEA metabolites on 11β-HSD1 dehydrogenase activity 
in HEK cells. HEK-293 cells stably expressing human 11β-HSD1 (AT6, A) or human 11β-
HSD1 and human H6PDH (HHH7, B) were incubated with 200 nM cortisone for 2 h (A) or 30 
min (B) in the presence of 7-oxygenated steroids. Enzyme activity was determined as described 
in “Materials and Methods”. One representative experiment out of four is shown. Data represent 
% conversion, whereby the activity of control cells incubated with vehicle was set to 100%. 
7keto-DHEA (), 7α-DHEA ({), 7β-DHEA (d). 
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11β-HSD1 activity is inhibited by its substrate 7-KC in THP-1 macrophages but not in AT6 and 
HHH7 cells 
The oxidized cholesterol metabolite 7-KC is a biologically relevant compound. It is one 
of the major oxysterols accumulated in foam cells of the atherosclerotic plaque and is enriched 
also in cholesterol containing processed (i.e. heat-treated) food (Brown and Jessup, 1999, Gill et 
al., 2008, Schroepfer, 2000). Recently, we and others showed that 11β-HSD1 is able to catalyze 
the interconversion of 7-KC and 7β-hydroxycholesterol in cellular systems and in the liver of the 
rat (Arampatzis et al., 2005, Hult et al., 2004, Schweizer et al., 2004). Based on the fact that 11β-
HSD1 accepts both cortisone and 7-KC as substrates with comparable kinetic properties, we 
expected that 7-KC acts as a potent competitive inhibitor of the 11β-HSD1 reductase activity. 
Surprisingly, we could not detect any inhibition of the enzyme in cell lysates or intact HEK-293 
cells stably expressing 11β-HSD1 or both 11β-HSD1 and H6PDH, even when 7-KC was 
supplied at high concentrations (Fig. 2A). In contrast, incubation of differentiated THP-1 
macrophages with 7-KC resulted in significantly decreased 11β-HSD1 activity (IC50 8.1 ± 0.9 
μM; Fig. 2A). 7-KC did not show cellular toxicity at the conditions applied as assessed by the 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and measurement of 
cellular protein (data not shown). 7β-OHC was also able to inhibit 11β-HSD1 reductase activity 
in THP-1 macrophage, although about half as efficiently as 7-KC, but not in HEK cells. 
Moreover, during revision of this manuscript a paper by Wamil et al. reported reduction of 7-KC 
by 11β-HSD1 and inhibition of the reduction of cortisone by 7-KC in 3T3-L1 adipocytes (Wamil 
et al., 2008). Why 7-KC and 7β-OHC inhibit 11β-HSD1 in THP-1 macrophages and 3T3-L1 
adipocytes but not in HEK cells is currently unclear, especially since 7-keto-DHEA and 7-
ketopregnenolone resulted in potent inhibition with comparable IC50 values both in macrophages 
and HEK cells (Fig. 2A). 7-hydroxy-DHEA metabolites were also weak inhibitors of 11β-HSD1 
reductase activity in differentiated THP-1 macrophages (Fig. 2B). Possible explanations for the 
cell-specific effect of 7-KC on 11β-HSD1 include differential metabolism of 7-KC (see below), 
differential post-translational modification of 11β-HSD1 and/or differences in the intracellular 
accumulation of oxysterols. 
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Figure 2.  Inhibition of 11β-HSD1 by 7-oxygenated DHEA and cholesterol metabolites. 
A.  Inhibition of 11β-HSD1 in differentiated THP-1 macrophages but not in HEK cells. Cells 
were incubated with 7-KC (20 μM) or 7-keto-DHEA (20 μM) and radiolabeled cortisone (200 
nM) for 30 min (HHH7), 2 h (AT6) or 6 h (THP-1). Enzyme activity was determined as 
described in “Materials and Methods”. Data are expressed as percentage of the conversion 
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detected with cells incubated with vehicle. Open bars, vehicle; filled bars, 7-KC 20 μM; hatched 
bars, 7-keto-DHEA 20μM. 
B.  Effect of 7-oxygenated DHEA and cholesterol metabolites on 11β-HSD1 reductase activity 
in differentiated THP-1 macrophages. Differentiated THP-1 macrophages were incubated with 1 
μM 7-keto-DHEA, 10 μM 7α-hydroxy-DHEA, 10 μM 7β-hydroxy-DHEA, 10 μM 7-KC or 10 
μM 7β-OHC in medium containing radiolabeled cortisone (200 nM) for 6 h. Enzyme activity 
was measured as described in “Materials and Methods”.   
 
Analysis of 7-oxycholesterol binding to 11β-HSD1 by 3D-modelling 
Our data and those of others show that 11β-HSD1 catalyzes the formation of 7β-OHC 
from 7-KC (Hult et al., 2004, Schweizer et al., 2004, Wamil et al., 2008). Based on our previous 
analysis (Nashev et al., 2007), this indicates that during catalysis 7-KC has the A ring oriented 
towards the interior of 11β-HSD1, which is opposite of that for corticosterone (Fig. 3A)(Zhang 
et al., 2005). Thus, we modeled 7-KC and 7β-OHC in 11β-HSD1 with their A ring oriented 
towards the interior of 11β-HSD1 as shown in Figure 3B and 3C. In each panel in Figure 3, we 
show the interactions of Ser170 and Tyr183 with the steroid substrates, Tyr183 with NADPH and 
Lys187 with the ribose hydroxyls. These are highly conserved interactions in SDRs (Jornvall et 
al., 1995, Sciotti et al., 2006). 
As reported by Zhang et al., Ser170 and Tyr183 on 11β-HSD1 are 3.1 Å and 2.8 Å, 
respectively, from the C11-hydroxyl on corticosterone (Zhang et al., 2005). The C11 hydroxyl is 
3.9 Å from the C4 atom on the nicotinamide ring on NADPH. Lys187 is 3.2 Å from each ribose 
hydroxyl on NADPH (Fig. 3A). 
Similar distances are found in the 11β-HSD1/NADPH 7-KC complex (Fig. 3B). Ser170 
and Tyr183 are 2.8 Å from the C7-ketone on 7-KC. Tyr183 is 3.8 Å from the nicotinamide C4. 
Lys187 is 3.6 Å from each ribose hydroxyl, which is a favorable distance, although it is a weaker 
hydrogen bond than is found in the 11β-HSD1 complex with corticosterone (Fig. 3A). 
In the 11β-HSD1/NADPH/7β-OHC complex, Ser170 and Tyr183 are 2.8 Å and 3.8 Å, 
respectively, from the 7β-hydroxyl (Fig. 3C). There are, however, two distances in the complex 
which would be expected to reduce catalysis of 7β-OHC by 11β-HSD1. First, the 7β-hydroxyl is 
4.5 Å from the nicotinamide C4. Second, the Lys187 side chain has rotated so that it is 5.1 Å from 
the NO3 ribose hydroxyl. The distances of these latter two key interactions in the catalytic site of 
the 11β-HSD1/NADPH/7β-OHC complex suggest a suboptimal interaction of 7β-OHC with 
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11β-HSD1 which may explain the less efficient catalysis by 11β-HSD1 of 7β-OHC compared 
with that of 11β-hydroxyglucocorticoids. 
 
 
 
Figure 3.  3D models of 7-KC and 7β-OHC in mouse 11β-HSD1. 
A. 11β-HSD1 complexed with corticosterone and NADPH (Zhang et al., 2005). In the crystal 
structure of 11β-HSD1, the D ring of corticosterone is orientated towards the interior of 11β-
HSD1. The catalytically active Ser170 and Tyr183 and the nicotinamide C4 are favorably 
positioned to interact with the 11β-hydroxyl on corticosterone. Lys187 is 3.2 Å from each ribose 
hydroxyl on NADPH. 
B. 11β-HSD1 complexed with 7-KC and NADPH. The A ring is orientated towards the interior 
of 11β-HSD1. As a result, the C7 and C11 positions on 7-KC flip so that the C7-ketone has 
favorable interactions with Ser170, Tyr183 and the nicotinamide C4. Lys187 is 3.6 Å from each 
ribose hydroxyl. 
C. 11β-HSD1 complexed with 7β-OHC and NADPH. The A ring is orientated towards the 
interior of 11β-HSD1. The 7β-hydroxyl on 7β-OHC is 2.8 Å and 3.8 Å, respectively, from Ser170 
and Tyr183. The 7β-hydroxyl is 4.5 Å from the nicotinamide C4, and Lys187 has rotated so that it 
is 5.1 Å from the NO3 ribose hydroxyl. These two unfavorable distances may contribute to 
suboptimal binding of 7β-OHC to 11β-HSD1. 
 
Also of importance for substrate binding and catalysis is the different orientation in 11β-
HSD1 of both cholesterol molecules compared with that of corticosterone. The interaction of 
11β-HSD1 with the corticosterone D ring, which has a C17 side chain containing a ketone at 
C20 and alcohol at C21, will be different than that for the A ring of two cholesterol analogs, 
which have a 3β-hydroxyl. These differences are likely to influence enzyme kinetics and may 
explain the absence of 7-OHC catalysis by 11β-HSD1 in intact HEK293 cells as due to post-
translational modifications, such as phosphorylation or glycosylation. Such post-translational 
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modifications of 11β-HSD1 would not affect binding or catalysis of glucocorticoids, and indeed, 
may even optimize catalytic efficiency, but they may interfere with binding of 7-oxycholesterols 
due to the different orientation in 11β-HSD1. 
 
Potential relevance of the 11β-HSD1-dependent metabolism of 7-KC 
11β-HSD1 preferentially converts 7-KC to 7β-OHC in the liver, where it may play a role 
in the detoxification of food-derived 7-KC by catalyzing the first step toward the formation of 
bile acids and subsequent excretion (Schweizer et al., 2004). 11β-HSD1-dependent metabolism 
of 7-KC might also be relevant in macrophages in the pathogenesis of atherosclerosis. It has been 
suggested that 7-KC is toxic and pro-atherogenic, for example by inhibiting cholesterol efflux 
from foam cells, inducing apoptosis and altering endothelial permeability (Brown and Jessup, 
1999, Jessup and Brown, 2005). The relative ratio of different oxysterol metabolites seems to be 
important for the final (patho)physiological output (Biasi et al., 2004, Steffen et al., 2006). Our 
efforts to elucidate 11β-HSD1-dependent 7-KC metabolism in macrophages have not yet 
succeeded, given the disappearance of added 7-KC without formation of significant amounts of 
7β-OHC (data not shown). This may be due to rapid subsequent metabolism of 7β-OHC formed 
by 11β-HSD1 to an unknown product; alternatively, the 11β-HSD1-mediated pathway may not 
be the exclusive route of 7-KC metabolism in macrophages (Jessup and Brown, 2005). Several 
recent reports suggest 27-hydroxylase as an important enzyme responsible for 7-KC metabolism, 
resulting in the formation of 7-keto-27-hydroxycholesterol (Brown et al., 2000, Lyons and 
Brown, 2001). This hypothesis, however, could not be confirmed in 27-hydroxylase deficient 
mice (Lyons et al., 2002), which showed enhanced hepatic metabolism of 7-KC. Nevertheless, 
the high concentration of 7-KC in macrophages of atherosclerotic plaques is expected to interfere 
with 11β-HSD1-dependent glucocorticoid activation and further studies are required to elucidate 
the relevance of 11β-HSD1 function in macrophages.  
 
Conclusions 
The present study emphasizes the importance of considering H6PDH in the analysis of 
the properties of 11β-HSD1 inhibitors. H6PDH can have a significant influence on the potency 
of pharmaceutical or natural compounds designed to decrease 11β-HSD1-dependent generation 
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of active glucocorticoids. Moreover, tissue-specific expression of H6PDH allows fine-tuned 
regulation of the 11β-HSD1-mediated interconversion both of glucocorticoids and of 7-
oxygenated steroids and sterols. It will be important to investigate the potential interference of 
systemically applied 11β-HSD1 inhibitors with these alternative (i.e. non-glucocorticoid) 
activities as well as that of 11β-HSD1 dehydrogenase, which may not be present in some tissues 
including brain and testis. 
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